Apogee Therapeutics, Inc. filings document a clinical-stage biotechnology issuer focused on antibody programs for inflammatory and immunology indications. The company’s Form 8-K disclosures cover operating results, Regulation FD clinical-data presentations for zumilokibart (APG777), APG279 and APG333 development activity, and material agreements related to public common-stock offerings.
Proxy materials cover annual meeting matters, director elections, board composition, executive compensation, equity awards and shareholder voting. The filings also identify APGE common stock on The Nasdaq Global Market and provide recurring capital-structure, governance, clinical or regulatory, and financial disclosures tied to the company’s research and development model.
Apogee Therapeutics, Inc. chief executive Michael Thomas Henderson reported planned stock sales under a Rule 10b5-1 trading plan. On February 11, 2026, he executed three open-market sales of Apogee common stock: 11,494 shares at a weighted average price of $62.96, 7,551 shares at $63.73, and 955 shares at $64.99.
The filing notes that these trades were made pursuant to a Rule 10b5-1 plan adopted on August 13, 2025, and that prices reflect weighted averages across multiple transactions within specified ranges. Following the last reported sale, Henderson directly beneficially owns 1,172,987 shares of Apogee common stock.
Michael Henderson filed a Form 144 indicating an intent to sell 60,000 shares of APGE common stock. The planned sale is through The Charles Schwab Corporation and is tied to an aggregate market value of $3,840,000, with an approximate sale date of February 11, 2026 on the Nasdaq.
The notice states these shares were acquired via RSU vesting between June 2, 2023 and December 14, 2023, with 60,000 securities acquired on June 2, 2023. The filing notes that 54,833,587 shares of the issuer’s common stock were outstanding. Over the prior three months, Henderson reported selling 40,000, 20,000 and 20,000 APGE common shares for gross proceeds of $3,000,312, $1,507,650 and $1,622,186, respectively.
Apogee Therapeutics, Inc. received an updated ownership report from several Wellington entities disclosing a sizeable institutional stake in its common stock. The Wellington group reports beneficial ownership of 4,746,585 shares of Apogee common stock, representing 8.66 % of the outstanding class.
The filing states Wellington has no sole voting or dispositive power over these shares. Instead, it reports shared voting power over up to 4,341,936 shares and shared dispositive power over up to 4,746,585 shares, held of record by Wellington investment-advisory clients in the ordinary course of business.
Apogee Therapeutics Chief Medical Officer Carl Dambkowski reported an option exercise and related share sales. On 02/04/2026, he exercised stock options for 4,125 shares of common stock at an exercise price of $22.86 per share.
On the same date, he sold multiple small blocks of Apogee common stock at weighted average prices of $64.88, $65.83, $66.85, $67.88 and $68.94 per share, under a Rule 10b5-1 trading plan adopted on September 22, 2025. After these transactions, he directly held 211,148 shares of common stock and 135,415 derivative securities (stock options) of Apogee Therapeutics.
Apogee Therapeutics, Inc. Chief Financial Officer Jane Henderson reported planned stock sales under a Rule 10b5-1 trading plan. On February 2, 2026, she sold 792 shares of common stock at a weighted average price of $65.21, 1,108 shares at $66.15, and 100 shares at $66.89.
The weighted average prices reflect multiple trades in ranges from $64.80 to $65.61 and from $65.84 to $66.75. After these transactions, she directly owned 183,371 shares of Apogee common stock.
The Vanguard Group has disclosed a significant stake in Apogee Therapeutics Inc. As of 12/31/2025, Vanguard reports beneficial ownership of 2,857,824 shares of Apogee common stock, representing 5.21% of the class.
Vanguard reports no sole voting or dispositive power. It has shared voting power over 374,247 shares and shared dispositive power over 2,857,824 shares. The holdings are for clients, who have rights to dividends and sale proceeds, with no single client exceeding 5% of the class.
Vanguard states the shares were acquired and are held in the ordinary course of business, not to change or influence control of Apogee. It also notes an internal realignment effective 01/12/2026, after which certain subsidiaries are expected to report beneficial ownership separately while pursuing the same investment strategies.
Apogee Therapeutics, Inc. insider filing shows a major share sale by an investment fund linked to company directors. Fairmount Healthcare Fund II L.P., managed by Fairmount Funds Management LLC, sold 1,750,000 shares of Apogee common stock on 01/22/2026 at $76.30 per share in an indirect transaction. After this sale, the fund is reported as indirectly holding 298,647 shares of common stock.
The filing also reports that Fairmount Healthcare Fund II L.P. indirectly holds 6,743,321 shares of non-voting common stock, which are convertible into Apogee common stock on a 1-for-1 basis, subject to a beneficial ownership cap of 9.99%, which can be increased to up to 19.99% with 61 days’ notice. Separately, director-affiliated individuals Tomas Kiselak and Peter Harwin are each shown as indirectly holding 51,166 shares of common stock. Fairmount, Kiselak, and Harwin disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
A holder of Apogee Therapeutics (symbol APGE) common stock filed a Form 144 notice to potentially sell 1,750,000 shares through broker Jefferies LLC on or about 01/22/2026 on the NASDAQ. The filing lists an aggregate market value for the planned sale of $133,525,000.00, based on current market prices, compared with 54,833,587 shares of the class outstanding. The shares were originally purchased in the initial public offering on 07/13/2023 from the issuer for cash, with payment dated 07/18/2023.
By signing the notice, the seller represents they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations, and acknowledges that intentional misstatements or omissions would be a federal criminal violation.
Apogee Therapeutics’ major shareholder Fairmount Funds has updated its ownership disclosure after a sizable share sale. Fairmount Healthcare Fund II L.P. and related parties now report beneficial ownership of up to 9.99% of Apogee’s common stock, using both common and non-voting common shares in the calculation and subject to a 9.99% beneficial ownership cap.
The filing shows Fairmount-related entities having voting and dispositive power over 6,031,979 shares of common stock, including shares issuable upon conversion of non-voting common stock. Fund II also holds 6,743,321 shares of non-voting common stock in total, which can convert to common stock within the ownership limits. On January 22, 2026, Fund II sold 1,750,000 shares of common stock in a block trade at $76.30 per share. Directors Peter Harwin and Tomas Kiselak each hold common shares and vested options but disclaim beneficial ownership of the option shares due to arrangements with Fairmount.
Apogee Therapeutics, Inc. Chief Executive Officer and director Michael Thomas Henderson reported open‑market sales of the company’s common stock. On January 14, 2026, he sold shares in multiple transactions at weighted average prices ranging from about $78.16 to $83.84 per share, under a pre‑arranged Rule 10b5-1 trading plan adopted on August 13, 2025. Following these sales, he reported beneficial ownership of 1,192,987 shares of Apogee common stock held directly.